European regulators have expanded the treatment scope of Amgen’s Xgeva to include the prevention of skeletal-related events in adults with multiple myeloma.
The Cancer Vanguard and Amgen have developed a simulation modelling tool to show health commissioners and trusts the financial benefits and challenges of delivering breast cancer medicines in a variety of community settings.